Although its acute (4-hour period) administration in overweight human subjects was associated with significant increase in energy expenditure (by ~8%) (216), a 28-day clinical trial investigating the efficacy of chronic use of L-796568 in overweight and obese non-diabetic men receiving the drug (350 mg/d) failed to display any significant changes in body composition or 24-hour energy expenditure (217)
Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect: Signs of an allergic reaction, like skin rash, hives with itching and red swollen blistered peeling skin with or without fever, wheezing, tightness in the chest or throat, trouble breathing, trouble swallowing, trouble talking, unusual hoarseness, or swelling of the mouth, face, lips, tongue, or throat
Unlike opioids, it does not act on the brains pain receptors but instead targets inflammation at its source
Combination therapy Emerging efficacy results of combination therapy with either isatuximab after daratumumab or daratumumab after isatuximab may show a different trend compared with the monotherapy approach